Categories Earnings, Health Care

Exact Sciences Corp. (EXAS): Q4 2019 Earnings Snapshot

— Exact Sciences Corp. (NASDAQ: EXAS) reported Q4 2019 earnings of $0.54 per share, vs. a loss of $0.35 expected.

— Total revenues were $295.6 million, vs. $283 million expected.

— Screening revenues increased 60% to $229.4 million.

— Cologuard test volume rose 63% to 477,000.

— Average Cologuard recognized revenue per test was $481.

— Average Cologuard cost per test was $123.

— Precision Oncology proforma revenue increased 14% to $119.1 million.

— FY2020 consolidated revenue is expected to be $1.61-1.64 billion.

— FY2020 Screening revenue is expected to be $1.125-1.15 billion.

— FY2020 Precision Oncology revenue is expected to be $485-495 million.

— EXAS shares gained 1.2% immediately following the announcement.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%

Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss

Key metrics from Nike’s (NKE) Q2 2025 earnings results

NIKE, Inc. (NYSE: NKE) reported total revenues of $12.4 billion for the second quarter of 2025, down 8% on a reported basis and down 9% on a currency-neutral basis. Net

FDX Earnings: FedEx Q2 2025 adjusted profit increases; revenue dips

Cargo giant FedEx Corporation (NYSE: FDX), which completed an organizational restructuring recently, announced financial results for the second quarter of 2025. Second-quarter earnings, excluding one-off items, were $4.05 per share,

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top